Characterizing the Retinal Microvasculature in Patients with Fabry Disease: a Prospective Observational Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorTechnical University of Munich

About this trial

This study aims to gain a deeper understanding of endothelial dysfunction in patients with Fabry disease through a prospective study of the retinal microvasculature and to identify an objective, non-invasive marker to assess disease severity and cardiovascular risk in patients.

The main questions addressed are: Do dynamic and static retinal vessel analysis parameters differ from those in healthy individuals? Can these parameters predict cardiovascular and/or Fabry-related events during follow-up? Do these parameters change during follow-up in patients with a non-stable disease?

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age > 18 years

Diagnosis of Fabry disease by genetic testing or GB3 activity in leukocytes.

Signed informed consent form

Disqualifiers

Active infection or cancer

Surgery less than 2 weeks prior to inclusion in the study

Known glaucoma

Lack of capacity to give consent; lack of informed consent.

Trial population

Patients included in this study are recruited through our in-house metabolic outpatient clinic (Stoffwechselambulanz), which specializes in the diagnosis, treatment, and long-term management of rare metabolic disorders, including Fabry disease. The clinic serves as a comprehensive care center, offering multidisciplinary services such as genetic counseling, laboratory diagnostics, and individualized treatment planning. Patients are identified and approached during routine follow-ups or initial consultations after confirmation of a Fabry disease diagnosis through genetic testing or measurement of globotriaosylceramide (Gb3) activity in leukocytes. This structured recruitment process ensures the inclusion of well-characterized patients who meet the study's eligibility criteria.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Dynamic retinal vessel analysis (DVA)

    Diagnostic test

    Dynamic retinal vessel analysis (DVA) is an established, non-invasive technique for evaluating the responsiveness of retinal vessels to flickering light stimuli. This technique allows for the measurement of changes in retinal vessel diameter in response to changes in blood flow, providing insight into the microcirculatory function of the retina. In the case of DVA, patients will asked to focus on a needle, and one arteriole and venule diameter were automatically and continuously recorded. Arteriole and venule segments between 0.5 to 1 mm will be analyzed approximately 2-disc diameters away from the optic nerve in a lower-temporal direction. The baseline recording will be 50 seconds, followed by a flickering phase of 20 seconds and then a recovery period of 80 seconds. Three of these cycles were performed. Based on this, we will calculate the percentage of maximum arteriolar (aFID) and venular dilation (vFID) to baseline.

  • Biochemistry and immune phenotyping

    Diagnostic test

    Collection of blood samples from participants for the purpose of performing clinical chemistry analysis. Peripheral blood mononuclear cells (PBMCs) will be isolated from the collected blood samples using standard techniques, such as density gradient centrifugation, and will be analyzed using fluorescence-activated cell sorting (FACS)

  • Questionnaires (Patient reported outcomes)

    Diagnostic test

    This study involves a comprehensive evaluation of life quality, pain, and gastrointestinal (GI) symptoms using a set of established and validated questionnaires. The tools employed include the SF-36 (Short Form-36 Health Survey) to assess overall health-related quality of life across multiple domains, the COMPASS-31 (Composite Autonomic Symptom Score) to evaluate autonomic dysfunction symptoms, and the Brief Pain Inventory (BPI) to measure pain severity and its impact on daily activities. Additionally, the Gastrointestinal Symptom Rating Scale (GSRS) is used to quantify the severity and frequency of GI symptoms, covering dimensions such as reflux, abdominal pain, indigestion, diarrhea, and constipation. Together, these questionnaires provide a multidimensional assessment of the patient's physical, emotional, and symptomatic experiences, allowing for a robust understanding of their health status and quality of life.

  • Cardio MRI

    Diagnostic test

    Cardiovascular magnetic resonance imaging (CMR or cardio MRI) will be utilized in patients with Fabry disease. This imaging technique will enable detailed assessment and monitoring of key cardiac abnormalities, including thickening of the heart walls, left ventricular hypertrophy, and decreased blood flow in the coronary vessels. Additionally, T1 relaxation time measurement will be conducted, offering a non-invasive means to detect myocardial tissue abnormalities such as fibrosis and sphingolipid accumulation, which are hallmarks of Fabry disease. Together, these measures provide a comprehensive evaluation of cardiac structure, function, and tissue characteristics in affected patients.

  • Optical coherence tomography (OCT)

    Diagnostic test

    Optical coherence tomography (OCT) is a non-invasive, high-resolution imaging technique that utilizes low-coherence light to capture cross-sectional images of the ocular fundus. Based on the principle of interferometry, OCT employs low-coherence light, which is scattered by the tissue, to produce detailed, high-resolution images of the retina and its layers. This technology enables precise visualization of the different retinal layers, including the nerve fiber layer, the ganglion cell layer, and the inner and outer plexiform layers. Additionally, OCT can be used to detect and monitor subtle structural changes in the retina, offering critical insights into retinal microarchitecture and potential manifestations of systemic diseases such as Fabry disease.

  • Echocardiography

    Diagnostic test

    Detection of signs of left ventricular hypertrophy, diastolic dysfunction, and valvular disease, which are common cardiac complications associated with Fabry disease, will be a key focus of the assessment. These abnormalities are indicative of the progressive cardiac involvement characteristic of the disease. Left ventricular hypertrophy reflects the thickening of the heart muscle, often caused by sphingolipid accumulation, while diastolic dysfunction highlights impaired relaxation and filling of the left ventricle. Valvular disease, including regurgitation or stenosis, further contributes to the cardiac burden in Fabry disease. Identifying and monitoring these conditions are essential for timely intervention and effective management of cardiac manifestations in affected patients.

  • 24 hour pulse wave analysis

    Diagnostic test

    Pulse wave analysis (PWA) is a non-invasive method used to assess the cardiovascular system. It uses a sensor to measure the pressure waves generated by the heart's contraction and the subsequent blood flow through the peripheral vessels. By analyzing these pressure waves, PWA can provide information about the elasticity of the arterial walls, the blood flow in the peripheral vessels, the blood pressure, and the arterial stiffness.

  • 24-hour blood pressure measurement

    Diagnostic test

    Blood pressure measurement to asses cardiovascular risk.

  • 1 hour ECG

    Diagnostic test

    One hour ECG to asses autonomic dysfunction in patients with Fabry disease.

  • Ophthalmological consultation

    Diagnostic test

    Evaluation and monitoring of ocular manifestations of Fabry disease.

  • Static retinal vessel analysis (SVA)

    Diagnostic test

    Comparable to DVA, SVA is a non-invasive and quick tool to examine the retinal microvasculature. SVA pictures will be analyzed using Vesselmap 2® (IMEDOS Systems GmbH, Jena, Germany). One eye will be examined, and three images will be taken with a focus on the optic disc at an angle of 50°. Roughly one disc diameter away from the optic disc, retinal veins and arterioles segments will be semi-automatically labeled. The Paar-Hubbard formula averages the central retinal arteriolar (CRAE) and central venular (CRVE) equivalents. The arteriolar-venular ratio will be calculated as CRAE/CRVE.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Change in Retinal Arteriolar Diameter (CRAE)

What will be measured: Central Retinal Arteriolar Equivalent (CRAE) in micrometers (µm). Unit of Measure: Micrometers (µm). How it will be reported: Mean CRAE values at baseline for Fabry disease patients compared with age- and sex-matched healthy controls.

Time frame
From enrollment (T0) to the occurrence of death or the end of the study, whichever comes first, assessed over an estimated period of up to 4 years. Measurements will be conducted annually, starting at T0, then at 1 year (T1), 2 year (T2), T3 and T4.
2

Change in Retinal Arteriolar Diameter (CRVE)

What will be measured: Central Retinal Arteriolar Equivalent (CRVE) in micrometers (µm). Unit of Measure: Micrometers (µm). How it will be reported: Mean CRAE values at baseline for Fabry disease patients compared with age- and sex-matched healthy controls.

Time frame
From enrollment (T0) to the occurrence of death or the end of the study, whichever comes first, assessed over an estimated period of up to 4 years. Measurements will be conducted annually, starting at T0, then at 1 year (T1), 2 year (T2), T3 and T4.
3

Change in arteriolar-venular ration (AVR)

What will be measured: AVR as a quotient out of CRAE/CRVE Unit of Measure: no unit How it will be reported: Mean or Median AVR values at baseline for Fabry disease patients compared with age- and sex-matched healthy controls.

Time frame
From enrollment (T0) to the occurrence of death or the end of the study, whichever comes first, assessed over an estimated period of up to 4 years. Measurements will be conducted annually, starting at T0, then at 1 year (T1), 2 year (T2), T3 and T4.
4

Change in Flicker-Induced Venular Dilation (vFID)

What will be measured: Maximum percentage change in retinal venular diameter during flicker stimulation. Unit of Measure: Percentage (%). How it will be reported: Mean vFID percentage change at baseline for Fabry disease patients compared with age- and sex-matched healthy controls.

Time frame
From enrollment (T0) to the occurrence of death or the end of the study, whichever comes first, assessed over an estimated period of up to 4 years. Measurements will be conducted annually, starting at T0, then at 1 year (T1), 2 year (T2), T3 and T4

Secondary outcomes

1

Correlation Between Retinal Vessel Parameters and Symptom Severity (DS3)

What will be measured: Correlation of static retinal vessel analysis parameters (CRAE, CRVE, AVR) and dynamic parameters (vFID, aFID) with the Fabry disease severity score (DS3, Giannini et al. 2009). Unit of Measure: Micrometers (µm) for CRAE, CRVE, AVR; percentage (%) for vFID and aFID; unitless for DS3 score (range 0-32). Measurement Tools: Dynamic Retinal Vessel Analyzer (IMEDOS Systems, Jena, Germany), Static Retinal Vessel Analyzer (IMEDOS Systems, Jena, Germany), and the DS3 scoring system. How it will be reported: Statistical correlation coefficients (e.g., Spearman or Pearson).

Time frame
Measurement at enrollment (T0)
2

Patients with Fabry disease and impaired retinal microcirculation Elevated Markers of Endothelial Dysfunction and Chronic Inflammation in Patients With Impaired Retinal Microcirculation

What will be measured: Concentration of markers of endothelial dysfunction (sICAM, sVCAM, Thrombomodulin, P-Selectin, E-Selectin, ADMA, SADMA, Endothelin-1) and chronic inflammation (IFN-β, IFN-λ1, TNF-α). Unit of Measure: Nanograms per milliliter (ng/mL) for most markers; other units (e.g., µmol/L for ADMA) as specified. Measurement Tools: ELISA, flow cytometry (e.g., FACS analysis for PBMCs). How it will be reported: Mean concentrations or median with interquartile range (IQR).

Time frame
Measurement at enrollment (T0)
3

Correlation Between Retinal Microcirculation Markers and Cardiac Damage

What will be measured: Static retinal vessel analysis parameters (CRAE, CRVE, AVR) and dynamic parameters (vFID, aFID) correlated with cardiac measurements ( thickness of interventricular septum, posterior wall thickness, left ventricular end diastolic diameter) and incidence of cardiovascular events (e.g., heart failure, arrhythmia). Unit of Measure: Micrometers (µm) for retinal vessel parameters; millimeters (mm) for cardiac measurements. Measurement Tools: Retinal vessel analyzers (IMEDOS Systems, Jena, Germany) and echocardiography. How it will be reported: Statistical correlation coefficients (e.g., Spearman or Pearson).

Time frame
Measurement at enrollment (T0)
4

Correlation Between Genetic Phenotypes and Retinal Vessel Parameters

What will be measured: Static retinal vessel analysis parameters (CRAE, CRVE, AVR) and dynamic parameters (vFID, aFID) correlated with genetic classifications (classical, non-classical Fabry disease) and pathogenicity of GLA gene variants. Unit of Measure: Micrometers (µm) for retinal vessel parameters; categorical classifications for genetic phenotypes (classical, non-classical). Measurement Tools: Retinal vessel analyzers (IMEDOS Systems, Jena, Germany) and genetic analysis using ACMG guidelines. How it will be reported: Mean retinal parameters for each genetic phenotype group; statistical correlations.

Time frame
Measurement at enrollment (T0)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.